APA-4
Revised 1/2018

CERTIFICATION OF EMERGENCY RULES
FILED WITH LEGISLATIVE SERVICES AGENCY
OTHNI LATHRAM, INTERIM DIRECTOR

Pursuant to Code of Alabama 1975, §§41-22-5(b) and 41-22-6(c)(2)a. and b.

I certify that the attached emergency (amendment, new rule, new chapter, repeal or adoption by reference) is a correct copy as promulgated and adopted on the **23** day of **MARCH 2020**.

AGENCY NAME: **Alabama State Board of Pharmacy**

RULE NO. AND TITLE: **680-X-2-.26 .01ER Emergency Prescription Refills**

EFFECTIVE DATE OF RULE: **March 23, 2020**

EXPIRATION DATE (If less than 120 days): **July 21, 2020**

NATURE OF EMERGENCY: **COVID - 19 State of Emergency**

STATUTORY AUTHORITY: Code of Ala 1975 §34-23-92

SUBJECT OF RULE TO BE ADOPTED ON PERMANENT BASIS ____ YES **X** NO

NAME, ADDRESS, AND TELEPHONE NUMBER OF PERSON TO CONTACT FOR COPY OF RULE:

Wendy Passmore, Operations Manager
111 Village Street, Birmingham, AL 35242
Phone : 205-981-4764
Email: wpassmore@albop.com

REC'D & FILED
MAR 23 2020
LEGISLATIVE SVC AGENCY

Donna C. Goldman
Signature of officer authorized to promulgate and adopt rules and regulations or his or her deputy

FILING DATE
(For APA Use Only)

Alabama State Board of Pharmacy

NOTICE OF INTENDED ACTION

AGENCY NAME:

Alabama Board of Pharmacy

RULE NO. & TITLE:

680-X-2-.26 Emergency Prescription Refills

INTENDED ACTION:

Amend rule for State of Emergency

SUBSTANCE OF PROPOSED ACTION:

The Alabama State Board of Pharmacy proposes to amend rule 680-X-2-.26 to maintain continuity of care during COVID 19 State of Emergency.

TIME, PLACE, MANNER OF PRESENTING VIEWS:

Not Applicable - Emergency Submission

FINAL DATE FOR COMMENT AND COMPLETION OF NOTICE:

Not Applicable - Emergency Submission

CONTACT PERSON AT AGENCY:

Wendy Passmore, Operations Manager
111 Village Street, Birmingham, Al 35242
Phone 205-981-4764 Fax 205-803-6481
Email - wpassmore@albop.com

Donna C. Yeatman, R.Ph. Executive Secretary

680-X-2-.26 .01ER **Emergency Prescription Refills.**

(1) If a pharmacist received a request for a prescription refill, the original of which is maintained in the pharmacy files, and the pharmacist is unable to readily obtain refill authorization from the prescriber, the pharmacist may dispense a one-time emergency refill of up to a 72 hour supply of the prescribed medication, provided that:

(a) The prescription is not a medicinal agent listed in Schedule II appearing in Title 20 Chapter 2.

(b) The prescription is not a medicinal agent listed in Schedule III appearing in Title 20 Chapter 2.

(c) The medication is essential to the maintenance of life or the continuation of therapy in a chronic condition including but not limited to drugs listed in the following categories, according to the latest edition of Facts and Comparisons, U.S.P./N.F., P.D.R. or A.M.A. Drug evaluation:

1. Blood Modifiers

(i) Iron Products

(ii) Oral Iron

(II) Parenteral Iron

(III) Iron Combinations (with Vitamins, with Liver, with B12 and Intrinsic Factor)

(ii) Folic Acid

(I) Leucovorin Calcium

(iii) Vitamin B12

(I) Cyanocobalamin

(II) Hydroxocobalamin

(III) Liver Preparations

(iv) Vitamin K

(v) Recombinant Human Erythropoietin

(vi) Colony Stimulating Factors

(I) Filgrastim

(II) Sargramostim

(vii) Antiplatelet Agents

(I) Dipyridamole

(II) Ticlopidine

(vii) Anticoagulants

(I) Heparin

(II) Coumarin and Indandione Derivatives

(ix) Heparin Antagonist

(I) Protamine Sulfate

(x) Tissue Plasminogen Activator

(xi) Thrombolytic Enzymes

(xii) Hemorheologic Agent

(xiii) Antithrombin

(xiv) Antihemophilic Products

(I) Antihemophilic factor

(II) Anti-inhibitor coagulant complex

(III) Factor IX complex (Human)

(xv) Hemostatics

(I) Systemic

(II) Topical

(xvi) Plasma Protein Fractions

(xvii) Dextran Adjunct

(xviii) Plasma Expanders

(xix) Perfluorochemical Emulsion

(xx) Hemin

2. Hormones

(i) Sex Hormones

(I) Estrogens

(II) Progestins

(III) Estrogens and Progestins, Combined

(IV) Oral Contraceptives

(V) Levonorgestrel Implant

(VI) Intrauterine Progesterone

(VII) Androgens

(VIII) Anabolic Steroids

(IX) Estrogen and Androgen Combinations

(X) Ovulation Stimulants

(XI) Gonadotropins

(XII) Chorionic Gonadotropin

(XIII) Gonadotropin Releasing Hormones

(XIV) Danazol

(ii) Growth Hormone

(iii) Pituitary (Growth Hormone) Test

(iv) Octreotide Acetate

(v) Posterior Pituitary Hormones

(I) Vasopressin Derivatives

(II) Oxytocics

(vi) Uterine Relaxant

(vii) Abortifacients

(I) Prostaglandins

(II) Sodium Chloride

(viii) Adrenal Cortical Steroids

(I) Corticotropin (ACTH)

(II) Mineralocorticoids

(III) Glucocorticoids

(ix) Adrenal Steroid Inhibitors

(x) Pituitary Function Test

(xi) Antidiabetic Agents

(I) Insulin

(II) Sulfonylureas

(xii) Glucose Elevating Agents

(I) Glucagon

(II) Diazoxide

(III) Glucose

(xiii) Alglucerase

(xiv) Thyroid Drugs

(I) Thyroid Hormones

(II) Iodine Products

(III) Antithyroid Agents

(xv) Calcitonin

(xvi) Etidronate Disodium

(xvii) Gallium Nitrate

3. Diuretics and Cardiovasculars

(i) Diuretics

(I) Carbonic Anhydrase Inhibitors

(II) Thiazides and Related Diuretics

(III) Loop Diuretics

(IV) Potassium Sparing Diuretics

(V) Diuretics Combinations

(VI) Osmotic Diuretics

(VII) Nonprescription Diuretics

(ii) Cardiac Glycosides

(iii) Amrinone

(iv) Antianginal Agents

(I) Combinations

(v) Antiarrhythmic Agents

(vi) Calcium Channel Blocking Agents

(vii) Peripheral Vasodilators

(I) Combinations

(viii) Drugs used in shock

(ix) Beta-Adrenergic Blocking Agents

(x) Alpha-Beta Adrenergic Blocking Agents

(xi) Antihypertensives

(I) Antiadrenergic Agents

I. Centrally Acting

II. Peripherally Acting

(II) Vasodilators

(III) Angiotensin Converting Enzyme Inhibitors

(IV) Agents for Pheochromocytoma

(V) Agents for Hypertensive Emergencies

(VI) Miscellaneous Agents

(VII) Combinations

(xii) Potassium Removing Resins

(xiii) Cardioplegia Solution

(xiv) Salt Substitutes

(xv) Edentate Disodium

(xvi) Antihyperlipidemic Agents

4. Respiratory Drugs

(i) Bronchodilators

(I) Sympathomimetics

(II) Xanthine Derivatives

(ii) Respiratory Inhalant Products

(I) Corticosteroids

(II) Mucolytics

(III) Anticholinergics

(IV) Miscellaneous

(iii) Nasal Decongestants

(I) Combinations

(iv) Intranasal Steroids

(v) Alpha Proteinase Inhibitor

(vi) Lung Surfactants

(vii) Antihistamines

(I) Miscellaneous Preparations

(II) Combined Preparations

(viii) Antitussives

(I) Narcotic

(II) Nonnarcotic

(ix) Expectorants

(x) Respiratory Combination Products

(I) Antiasthmatic Combinations

I. Xanthine Combinations

A. Capsules and Tablets

B. Liquids

II. Xanthine Sympathomimetic Combinations

A. Capsules and Tablets

B. Liquids

(xi) Upper Respiratory Combinations

(I) Decongestant Combinations

(II) Pediatric Decongestant Combinations

(III) Antihistamine and Analgesic Combinations

(IV) Decongestants and Antihistamines

I. Sustained Release

II. Pediatric sustained release

III. Capsules and Tablets

IV. Liquids

V. Pediatric

(V) Decongestant, Antihistamine and Analgesic

I. Pediatric

(VI) Decongestant, Antihistamine and Anticholinergic

I. Sustained release

II. Miscellaneous

III. Pediatric

(VII) Cough Preparations

I. Antitussive combinations

A. Capsules and Tablets

B. Liquids

II. Expectorant Combinations

A. Capsules and Tablets

B. Liquids

III. Antitussive and Expectorants

A. Narcotic

B. Nonnarcotic

IV. Antitussive and Expectorant Combinations

A. With Decongestants

B. With Antihistamines

C. With Decongestants and Antihistamines

V. Pediatric

5. Central Nervous System Drugs

(i) CNS Stimulants

(I) Analeptics

(II) Amphetamines

(III) Anorexiants

(IV) Nonprescription Diet Aids

(ii) Analgesics

(I) Narcotic Agonist Analgesics

(II) Narcotic Anagenic Combinations

(III) Narcotic Agonist-Antagonist Analgesics

(IV) Central Analgesics

(V) Acetaminophen

(VI) Salicylates

(VII) Nonnarcotic Analgesic Combinations

(VIII) Nonsteroid Anti-Inflammatory Agents

(IX) Antirheumatic Agents

(X) Agents for Gout

(XI) Agents for Migraines

I. Combinations

(iii) Antiemetic/Antivertigo Agents

(I) Antidopaminergics

(II) Anticholinergics

(III) Miscellaneous

(IV) Combinations

(iv) Psychotherapeutic Drugs

(I) Antianxiety Agents

I. Benzodiazepines

II. Miscellaneous

(II) Antidepressants

I. Tricyclics

II. MAO Inhibitors

(III) Antipsychotic Agents

I. Phenothiazines

II. Thioxanthenes

(IV) Miscellaneous Psychotherapeutic Agents

I. Agents

(V) Sedative and Hypnotics

(VI) Nonbarbiturates

I. Benzodiazepines

(VII) Nonprescription Sleep Aids

(VIII) Barbiturates

(v) General Anesthetics

(I) Barbiturates

(II) Nonbarbiturates

(III) Gases

(IV) Volatile Liquids

(vi) Anticonvulsants

(I) Hydantoins

(II) Succinimides

(III) Oxazolidinediones

(IV) Benzodiazepines

(V) Miscellaneous

(vii) Muscle Relaxants

(I) Adjuncts to Anesthesia

I. Nondepolarizing Agents

II. Depolarizing Agents

(II) Skeletal

(III) Skeletal Combinations

(viii) Antiparkinson Agents

(I) Anticholinergics

6. Gastrointestinal Drugs

(i) Antacids

(I) Combinations

(ii) Sucralfate

(iii) Gastrointestinal Anticholinergics/Antispasmodics

(I) Combinations

(iv) Histamine H2 Antagonists

(v) Prostaglandins

(vii) GI Stimulants

(I) Metoclopramide

(II) Dexpanthenol

(viii) Digestive Enzymes

(ix) Gastric Acidifiers

(x) Choleretics

(xi) Hydrocholeretics

(I) Combinations

(xii) Miscellaneous Digestive Products

(xiii) Gallstone Solubilizing Agents

(I) Chenodiol

(II) Ursodiol

(III) Monoctanoin

(xiv) Laxatives

(I) Saline

(II) Stimulant

(III) Bulk

(IV) Emollient

(V) Fecal Softeners

(VI) Hyperosmolar Agents

(VII) Enemas

(VIII) C02 Releasing Suppositories

(IX) Bowel Evacuants

(X) Lactulose

(XI) Combinations

(xv) Antidiarrheals

(I) Diphenoxylate/Atropine

(II) Loperamide

(III) Bismuth Subsalicylate

(IV) Combinations

(xvi) Mesalamine

7. Antineoplastic Agents

(i) Chemotherapeutic Regimens

(ii) Alkylating Agents

(I) Nitrogen Mustards

I. Mechlorethamine HCI

II. Chlorambucil

III. Melphalan

IV. Cyclophosphamide

V. Uracil Mustard

(II) Nitrosoureas

I. Lomustine

II. Carmustine

III. Streptococci

(III) Thiotepa

(IV) Busulfan

(V) Pipobroman

(VI) Cisplatin

(iii) Antimetabolite

(I) Methotrexate

(II) Fluorouracil and Floxuridine

(III) Cytarabine

(IV) Mercaptopurine

(V) Thioguanine

(iv) Hormones

(I) Androgens

I. Testolactone

(II) Progestins

I. Megestrol Acetate

II. Medroxyprogesterone Acetate

(III) Estrogens

I. Diethylstilbestrol Diphosphate

II. Polyestradiol Phosphate

(IV) Estrogen/Nitrogen Mustard

I. Estramustine Phosphate

(V) Antiestrogen

I. Tamoxifen

(VI) Gonadotropin Hormone-Releasing Antigen

I. Leuprolide Acetate

(v) Antibiotics

(I) Bleomycin Sulfate

(II) Doxorubicin HCI

(III) Daunorubicin HCI

(IV) Mitoxantrone HCI

(V) Mitomycin

(VI) Dactinomycin

(VII) Plicamycin

(vi) Mitotic Inhibitors

(I) Etoposide

(II) Vincristine Sulfate

(III) Vinblastine Sulfate

(vii) Radiopharmaceuticals

(I) Solium Iodide I

(II) Sodium Phosphate P

(III) Chromic Phosphate P

(viii) Miscellaneous

(I) Interferon Alfa-2a

(II) Interferon Alfa-2b

(III) Hydroxyurea

(IV) Procarbazine HCI

(V) Dacarbazine

(VI) Mitotane

(VII) Asparaginase

(vix) NCI Investigational Agents

(d) The dispensing pharmacist creates a written prescription order containing all of the prescription information required by federal and state statutes, rules and regulations.

(e) The dispensing pharmacist notifies the prescriber orally or in writing of the emergency dispensing within seventy-two (72) hours after such dispensing.

(2) This rule is adopted jointly by the Board of Pharmacy and Board of Medical Examiners.

(3) Only during the State of Emergency as declared by the Governor of the State of Alabama relating to the COVID-19 virus, the Alabama Board of Pharmacy will authorize pharmacists to process emergency prescription refills for a 30-day supply of maintenance medications under the following requirements:

1) The pharmacist is unable to readily obtain refill authorization from the prescriber.
2) The original prescription is maintained in the dispensing pharmacy's files.
3) The prescription is not a medicinal agent listed in Schedule II.
4) The medication is essential to the maintenance of life or the continuation of therapy in a chronic condition.
5) The dispensing pharmacist creates a written prescription order containing all of the prescription information required by federal and state statutes, rules and regulations.

6) The dispensing pharmacist notifies the prescriber orally or in writing of the emergency dispensing within seventy-two (72) hours after such dispensing.

Author: ~~Jerry Moore,~~ Donna C. Yeatman, R.Ph. Executive Secretary
Statutory Authority: Code of Ala. 1975, §34-23-92.
History: Adopted: October 5, 1993; effective November 25, 1993.
Emergency Amendment March 23, 2020 effective until July 21, 2020